RxDoctor Payments Data

Amy Randolph

Family · Gastonia, NCNPI 1285019000

Payments from drug & device makers

$2,162in general payments, 2019–2025

Across 104 payments — averaging $20.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$242
  • Regeneron Healthcare Solutions, Inc.$212
  • Verona Pharma, Inc.$150
  • Actelion Pharmaceuticals US, Inc.$126
  • AstraZeneca$126
  • Novo Nordisk$113
  • plus $1K from 25 others

What the payments were for

  • Food & beverage$2,162100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,162 in reported general payments places this provider in the 80th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$26,402
Medicare patients
177
Services billed
383

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide108$128,731
JardianceEmpagliflozin64$72,476
Trelegy ElliptaFluticasone/Umeclidin/Vilanter52$63,080
EliquisApixaban46$49,157
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$26,325
MounjaroTirzepatide18$19,254
SymbicortBudesonide/Formoterol Fumarate41$12,850
LinzessLinaclotide14$11,964
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$10,309
Repatha SureclickEvolocumab18$9,992
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$8,626
Tresiba Flextouch U-100Insulin Degludec12$8,023
TradjentaLinagliptin13$6,696
VascepaIcosapent Ethyl12$5,211
Albuterol Sulfate HfaAlbuterol Sulfate190$5,036

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$113$128,731108 claims
Boehringer IngelheimJardiance, Tradjenta$34$79,17277 claims
GSKTrelegy Ellipta, Anoro Ellipta$242$71,70764 claims
PfizerEliquis$94$49,15746 claims
AstraZenecaBreztri Aerosphere, Symbicort$126$39,17560 claims
Lilly USA, LLCMounjaro$111$19,25418 claims
AbbVieLinzess, Synthroid$21$13,45832 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,522 family providers in North Carolina.

Other family in Gastonia

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →